Miguel Medina

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5753714/publications.pdf

Version: 2024-02-01

104 papers	8,171 citations	57758 44 h-index	51608 86 g-index
115 all docs	115 docs citations	115 times ranked	10418 citing authors

#	Article	IF	Citations
1	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
2	Residence, Clinical Features, and Genetic Risk Factors Associated with Symptoms of COVID-19 in a Cohort of Older People in Madrid. Gerontology, 2021, 67, 281-289.	2.8	36
3	Long runs of homozygosity are associated with Alzheimerâ€™s disease. Translational Psychiatry, 2021, 11, 142.	4.8	6
4	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
5	Genomic Characterization of Host Factors Related to SARS-CoV-2 Infection in People with Dementia and Control Populations: The GR@ACE/DEGESCO Study. Journal of Personalized Medicine, 2021, 11, 1318.	2.5	7
6	Prodromal Alzheimerâ€™s Disease: Constitutive Upregulation of Neuroglobin Prevents the Initiation of Alzheimerâ€™s Pathology. Frontiers in Neuroscience, 2020, 14, 562581.	2.8	8
7	Neuroanatomical signature of superâ€ageing: Structural brain study of youthful episodic memory in people over the age of 80. Alzheimer's and Dementia, 2020, 16, e041915.	0.8	1
8	APOEâ€Îµ4 and hippocampal volume in the cognitively healthy elderly: Longitudinal analysis reveals origins of apparent crossâ€sectional differences. Alzheimer's and Dementia, 2020, 16, e042680.	0.8	0
9	Editorial: Untangling the Role of Tau in Physiology and Pathology. Frontiers in Aging Neuroscience, 2020, 12, 146.	3.4	2
10	Tauopathy Analysis in P301S Mouse Model of Alzheimer Disease Immunized with DNA and MVA Poxvirus-Based Vaccines Expressing Human Full-Length 4R2N or 3RC Tau Proteins. Vaccines, 2020, 8, 127.	4.4	8
11	Effects of commonly prescribed drugs on cognition and mild cognitive impairment in healthy elderly people. Journal of Psychopharmacology, 2019, 33, 965-974.	4.0	9
12	Genomeâ€wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. Alzheimer's and Dementia, 2019, 15, 1333-1347.	0.8	111
13	Role of tau N-terminal motif in the secretion of human tau by End Binding proteins. PLoS ONE, 2019, 14, e0210864.	2.5	31
14	The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?. Acta Neuropathologica Communications, 2019, 7, 31.	5.2	49
15	Effects of Thioflavin T and GSK-3 Inhibition on Lifespan and Motility in a Caenorhabditis elegans Model of Tauopathy. Journal of Alzheimer's Disease Reports, 2019, 3, 47-57.	2.2	9
16	Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment. Biomolecules, 2019, 9, 734.	4.0	41
17	Bi-directional genetic modulation of GSK-3Î² exacerbates hippocampal neuropathology in experimental status epilepticus. Cell Death and Disease, 2018, 9, 969.	6.3	32
18	Secretion of full-length Tau or Tau fragments in cell culture models. Propagation of Tau in vivo and in vitro. Biomolecular Concepts, 2018, 9, 1-11.	2.2	14

#	Article	IF	Citations
19	An Overview of the Role of Lipofuscin in Age-Related Neurodegeneration. Frontiers in Neuroscience, 2018, 12, 464.	2.8	247
20	An Overview on the Clinical Development of Tau-Based Therapeutics. International Journal of Molecular Sciences, 2018, 19, 1160.	4.1	120
21	Tau Assembly into Filaments. Methods in Molecular Biology, 2018, 1779, 447-461.	0.9	4
22	Detecting Circulating MicroRNAs as Biomarkers in Alzheimerâ€™s Disease. Methods in Molecular Biology, 2018, 1779, 471-484.	0.9	4
23	The Dimensional Structure of Subjective Cognitive Decline. Neuromethods, 2018, , 45-62.	0.3	2
24	MicroRNAs in Neurodegenerative Diseases. International Review of Cell and Molecular Biology, 2017, 334, 309-343.	3.2	151
25	Toward common mechanisms for risk factors in Alzheimer's syndrome. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 571-578.	3.7	23
26	What is the evidence that tau pathology spreads through prion-like propagation?. Acta Neuropathologica Communications, 2017, 5, 99.	5.2	272
27	A Novel Neuroprotection Target With Distinct Regulation in Stroke and Alzheimerâ€™s Disease. , 2017, , 123-147.		3
28	Atypical, non-standard functions of the microtubule associated Tau protein. Acta Neuropathologica Communications, 2017, 5, 91.	5.2	157
29	EuroTau: towing scientists to tau without tautology. Acta Neuropathologica Communications, 2017, 5, 90.	5.2	8
30	Clinical Relevance of Specific Cognitive Complaints in Determining Mild Cognitive Impairment from Cognitively Normal States in a Study of Healthy Elderly Controls. Frontiers in Aging Neuroscience, 2016, 8, 233.	3.4	14
31	New Features about Tau Function and Dysfunction. Biomolecules, 2016, 6, 21.	4.0	67
32	Specific Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2016, 52, 271-281.	2.6	77
33	Tau Phosphorylation as a Therapeutic Target in Alzheimerâ€™s Disease. , 2016, , 327-341.		1
34	Protocols for Monitoring the Development of Tau Pathology in Alzheimerâ€™s Disease. Methods in Molecular Biology, 2016, 1303, 143-160.	0.9	3
35	Recent developments in tau-based therapeutics for Alzheimerâ€™s disease and related dementsia. SpringerPlus, 2015, 4, L14.	1.2	0
36	Further understanding of tau phosphorylation: implications for therapy. Expert Review of Neurotherapeutics, 2015, 15, 115-122.	2.8	37

#	Article	IF	Citations
37	Additional mechanisms conferring genetic susceptibility to AlzheimerÃ¢â‚¬â„¢s disease. Frontiers in Cellular Neuroscience, 2015, 9, 138.	3.7	27
38	The role of extracellular Tau in the spreading of neurofibrillary pathology. Frontiers in Cellular Neuroscience, 2014, 8, 113.	3.7	130
39	Is Tau a Prion-Like Protein?. Journal of Alzheimer's Disease, 2014, 40, S1-S3.	2.6	8
40	The need for better AD animal models. Frontiers in Pharmacology, 2014, 5, 227.	3.5	21
41	New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease. Expert Opinion on Therapeutic Targets, 2014, 18, 69-77.	3.4	39
42	New perspectives on the role of tau in Alzheimer's disease. Implications for therapy. Biochemical Pharmacology, 2014, 88, 540-547.	4.4	101
43	Bioactive prenylated phenyl derivatives derived from marine natural products: novel scaffolds for the design of BACE inhibitors. MedChemComm, 2014, 5, 474-488.	3.4	6
44	Longitudinal Assessment of a Transgenic Animal Model of Tauopathy by FDG-PET Imaging. Journal of Alzheimer's Disease, 2014, 40, S79-S89.	2.6	8
45	A Longitudinal FDG-PET Study of Transgenic Mice Overexpressing GSK- 3β in the Brain. Current Alzheimer Research, 2014, 11, 175-181.	1.4	13
46	Understanding the relationship between GSK-3 and Alzheimerâ€™s disease: a focus on how GSK-3 can modulate synaptic plasticity processes. Expert Review of Neurotherapeutics, 2013, 13, 495-503.	2.8	28
47	Evidence for a new binding mode to GSK-3: Allosteric regulation by the marine compound palinurin. European Journal of Medicinal Chemistry, 2013, 60, 479-489.	5.5	57
48	Use of Okadaic Acid to Identify Relevant Phosphoepitopes in Pathology: A Focus on Neurodegeneration. Marine Drugs, 2013, 11, 1656-1668.	4.6	27
49	Discussion. Plastic and Reconstructive Surgery, 2012, 129, 835-837.	1.4	7
50	Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3Î² by Tideglusib. Journal of Biological Chemistry, 2012, 287, 893-904.	3.4	190
51	Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study. Journal of Alzheimer's Disease, 2012, 33, 205-215.	2.6	248
52	New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidatesâ€”Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology, 2012, 20, 127-150.	3.9	285
53	Deconstructing GSK-3: The Fine Regulation of Its Activity. International Journal of Alzheimer's Disease, 2011, 2011, 1-12.	2.0	113
54	Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies. Frontiers in Molecular Neuroscience, 2011, 4, 24.	2.9	95

#	Article	IF	Citations
55	Recent Developments in Tau-Based Therapeutics for Neurodegenerative Diseases. Recent Patents on CNS Drug Discovery, 2011, 6, 20-30.	0.9	25
56	Overcoming Cell Death and Tau Phosphorylation Mediated by PI3KInhibition: A Cell Assay to Measure Neuroprotection. CNS and Neurological Disorders - Drug Targets, 2011, 10, 208-214.	1.4	13
57	Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimers Disease. Current Pharmaceutical Design, 2010, 16, 2790-2798.	1.9	80
58	NP7 protects from cell death induced by oxidative stress in neuronal and glial midbrain cultures from parkin null mice. FEBS Letters, 2009, 583, 168-174.	2.8	9
59	Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1549-1556.	4.8	116
60	Potent Î²-Amyloid Modulators. Neurodegenerative Diseases, 2008, 5, 153-156.	1.4	42
61	A Î´-Catenin Signaling Pathway Leading to Dendritic Protrusions. Journal of Biological Chemistry, 2008, 283, 32781-32791.	3.4	58
62	Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Current Opinion in Drug Discovery & Development, 2008, 11, 533-43.	1.9	32
63	Glycogen Synthase Kinase-3 (GSK-3) Inhibitory Activity and Structureâ€“Activity Relationship (SAR) Studies of the Manzamine Alkaloids. Potential for Alzheimerâ€™s Disease. Journal of Natural Products, 2007, 70, 1397-1405.	3.0	123
64	Manzamine B and E and Ircinal A Related Alkaloids from an IndonesianAcanthostrongylophoraSponge and Their Activity against Infectious, Tropical Parasitic, and Alzheimer's Diseases. Journal of Natural Products, 2006, 69, 1034-1040.	3.0	129
65	Dual Binding Site Acetylcholinesterase Inhibitors: Potential New Disease-Modifying Agents for AD. Journal of Molecular Neuroscience, 2006, 30, 85-88.	2.3	31
66	Donepezilâ€“tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Bioorganic and Medicinal Chemistry, 2005, 13, 6588-6597.	3.0	145
67	Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO Journal, 2005, 24, 1706-1716.	7.8	105
68	Design, Synthesis, and Biological Evaluation of Dual Binding Site Acetylcholinesterase Inhibitors:â€‰ New Disease-Modifying Agents for Alzheimer's Disease. Journal of Medicinal Chemistry, 2005, 48, 7223-7233.	6.4	203
69	Neuronal membrane cholesterol loss enhances amyloid peptide generation. Journal of Cell Biology, 2004, 167, 953-960.	5.2	308
70	P4-428 TDZDS: GSK3Î² inhibitors as therapeutic agents for Alzheimer's disease and other tauopathies. Neurobiology of Aging, 2004, 25, S596.	3.1	3
71	Wnt-1 expression in PC12 cells induces exon 15 deletion and expression of L-APP. Neurobiology of Disease, 2004, 16, 59-67.	4.4	12
72	RIPped out by presenilin-dependent Î³-secretase. Cellular Signalling, 2003, 15, 829-841.	3.6	59

#	Article	IF	Citations
73	RhoA/ROCK regulation of neuritogenesis via profilin IIaâ€“mediated control of actin stability. Journal of Cell Biology, 2003, 162, 1267-1279.	5.2	209
74	C455R notch3 mutation in a Colombian CADASIL kindred with early onset of stroke. Neurology, 2002, 59, 277-279.	1.1	62
75	Parkin Localizes to the Lewy Bodies of Parkinson Disease and Dementia with Lewy Bodies. American Journal of Pathology, 2002, 160, 1655-1667.	3.8	299
76	Brain armadillo protein ?-catenin interacts with Abl tyrosine kinase and modulates cellular morphogenesis in response to growth factors. Journal of Neuroscience Research, 2002, 67, 618-624.	2.9	51
77	WIP regulates N-WASP-mediated actin polymerization and filopodium formation. Nature Cell Biology, 2001, 3, 484-491.	10.3	251
78	?-catenin is a nervous system-specific adherens junction protein which undergoes dynamic relocalization during development. Journal of Comparative Neurology, 2000, 420, 261-276.	1.6	68
79	Presenilin Affects Arm/Î²-Catenin Localization and Function in Drosophila. Developmental Biology, 2000, 227, 450-464.	2.0	51
80	Hemizygosity of Î´-Catenin (CTNND2) Is Associated with Severe Mental Retardation in Cri-du-Chat Syndrome. Genomics, 2000, 63, 157-164.	2.9	168
81	Î´-catenin, an Adhesive Junctionâ€“associated Protein Which Promotes Cell Scattering. Journal of Cell Biology, 1999, 144, 519-532.	5.2	185
82	Expression of Presenilin 1 in nervous system during rat development. Journal of Comparative Neurology, 1999, 410, 556-570.	1.6	37
83	Expression of Presenilin 1 in nervous system during rat development. Journal of Comparative Neurology, 1999, 410, 556-570.	1.6	3
84	A Novel Gene in the Armadillo Family Interacts with Presenilin 1. , 1998, , 171-180.		0
85	Presenilin 1 interaction in the brain with a novel member of the Armadillo family. NeuroReport, 1997, 8, 1489-1494.	1.2	233
86	Presenilin 1 interaction in the brain with a novel member of the Armadillo family. NeuroReport, 1997, 8, 2085-2090.	1.2	258
87	Protein kinases involved in the phosphorylation of human tau protein in transfected COS-1 cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1996, 1316, 43-50.	3.8	8
88	The in vitro formation of recombinant Ï„ polymers. Molecular and Chemical Neuropathology, 1996, 27, 249-258.	1.0	33
89	Polymerization of Ï„ into Filaments in the Presence of Heparin: The Minimal Sequence Required for Ï„ â€•Ï„ Interaction. Journal of Neurochemistry, 1996, 67, 1183-1190.	3.9	352
90	Strong buffering capacity of insect cells. Implications for the baculovirus expression system. Cytotechnology, 1995, 17, 21-26.	1.6	15

#	Article	IF	Citations
91	The role of tau phosphorylation in transfected COS-1 cells. Molecular and Cellular Biochemistry, 1995, 148, 79-88.	3.1	32
92	Glycogen synthase kinase 3 phosphorylates recombinant human tau protein at serine-262 in the presence of heparin (or tubulin). FEBS Letters, 1995, 372, 65-68.	2.8	44
93	Identification of Protein Kinases That Modify Specific Epitopes. Analytical Biochemistry, 1994, 223, 159-161.	2.4	2
94	Unprocessed foot-and-mouth disease virus capsid precursor displays discontinuous epitopes involved in viral neutralization. Journal of Virology, 1994, 68, 4557-4564.	3.4	28
95	Induction of an Immune Response to Transmissible Gastroenteritis Coronavirus Using Vectors with Enteric Tropism. Advances in Experimental Medicine and Biology, 1994, 342, 455-462.	1.6	0
96	The Two Species of the Foot-and-Mouth Disease Virus Leader Protein, Expressed individually, Exhibit the Same Activities. Virology, 1993, 194, 355-359.	2.4	147
97	Modifications of the 5' untranslated region of foot-and-mouth disease virus after prolonged persistence in cell culture. Virus Research, 1992, 26, 113-125.	2.2	84
98	A serine proteinase in Drosophila embryos: Yolk localization and developmental activation. Insect Biochemistry, 1989, 19, 687-691.	1.8	19
99	The Maternal Origin of Acid Hydrolases in Drosophila and Their Relation with Yolk Degradation. (Drosophila/acid hydrolases/developmental regulation/yolk degradation/mitochondria). Development Growth and Differentiation, 1989, 31, 241-247.	1.5	29
100	Drosophila cathepsin B-like proteinase: A suggested role in yolk degradation. Archives of Biochemistry and Biophysics, 1988, 263, 355-363.	3.0	81
101	Glycogen Synthase Kinase 3: A Target for Novel Mood Disorder Treatments. , 0, , 125-154.		34
102	Protein Kinase Assays for Drug Discovery. , 0, , 189-201.		0
103	The Role of Glycogen Synthase Kinase-3 (GSK-3) in Alzheimerâ€™s Disease. , 0, , .		4
104	Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment. SSRN Electronic Journal, 0, , .	0.4	3